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Purpose: To prepare and evaluate new sustained release formulations of indomethacin 
based on extracts of propolis (bee glue). 
Methods: Standardization of propolis (bee glue) extracts was performed by high performance 
liquid chromatography (HPLC) and determination of the values of fat and fixed oils. Several 
indomethacin capsule formulations (F1 - F18) containing varying amounts of chloroform (0.75 
- 75 mg) and ethanol extracts (30 - 75 mg) of propolis were prepared. The dissolution rate of 
the formulations was evaluated by USP dissolution (rotating basket) method I  and the 
release data subjected to various kinetic models. Probable interaction between the drug and 
propolis extracts was studied by differential scanning calorimetry (DSC). 
Results: The results show that, although the release rate of formulations F1 - F7 did not 
show any significant difference (p < 0.05) compared to F18 as blank, the other formulations 
did. DSC results indicate that incorporation of propolis extract in the formulations lowered 
indomethacin melting point by between 5 and 30 ºC, indicating interaction between the drug 
and the waxy extract. Kinetic analysis of the in vitro release data of the formulations showed 
that the best-fit drug release model varied with the drug:propolis extract ratio of the 
formulations.   
Conclusion: Formulation F13 (with equal proportion of drug and bee glue extract) came out 
best from the dissolution test for indomethacin extended-release capsules as it exhibited zero 
order kinetics.  This fpormulation is therefore suitable for further development as a matrix 
formulation for controlled  release. 
 
Keywords: Propolis (bee glue), Indomethacin, Controlled release, Zero order kinetics, Waxy 
materials 
 





*Corresponding author: Tel: 0098 912 145 2220 E-mail: shonary@mazums0ac.ir, shonary@yahoo.com
Honary et al  
Trop J Pharm Res, October 2011;10(5): 544 
INTRODUCTION 
 
Propolis (bee glue) is the generic name for 
the resinous substance collected by honey 
bees from various plant sources. It is a 
strongly adhesive, resinous substance used 
by bees to seal holes in their hives and 
protect entry against intruders [1]. In general, 
propolis is composed of 50 % resin and 
vegetable balsam, 30 % wax, 10 % essential 
and aromatic oils, 5 % pollent and 5% various 
other substances, including organic debris.  
 
Raw propolis is processed by water washing 
and dissolving in 95 % ethanol to remove 
wax and organic debris; the resulting mixture 
is often known as propolis tincture, “propolis 
balsam” or ethanol extract of propolis (EEP)
 
[2]. The recorded use of propolis dates to as 
far as 300 BC and has continued as topical 
home remedies, as well as an ingredient in 
toothpaste and dental floss, and as a health-
food/dietary supplement in various dosage 
forms - tablets, capsules, ampoules and 
syrups [3]. The United States Department of 
Agriculture describes propolis as follows:  
“….a gum that is gathered by bees from 
various plants. It may vary in color from light 
yellow to dark brown; it may cause staining of 
the comb or frame and may be found in 
extracted honey” [4].  
 
Indomethacin is a well known non-steroidal 
anti inflammatory drug, administered by the 
oral route. In the last few decades, oral 
sustained-release dosage forms have been a 
focus of interest. Waxy materials have major 
applications in sustained release systems. 
Examples include hydrogenated oils [5], 
glyceryl stearate [6] and fatty alcohols [7]. 
Matrix delivery systems utilizing waxy 
materials usually employ a core of drug 
embedded in the wax or a compressed 
physical blend of drug and matrix forming 
agent. Several inert semi–solid excipients 
such as animal or vegetable waxes are 





Indomethacin microspheres coated with ethyl 




gelatin-cellulose acetate phthalate 
microcapsules prepared by complex 
coacervation method have been employed to 
fabricate sustained release indomethacin 
tablets that effectively reduced rat stomach 
irritation compared to conventional 
indomethacin formulations [10]. Extended 
release lipophilic microspheres of 
indomethacin prepared with cetostearyl 
alcohol, stearyl alcohol, and cetyl alcohol in 
varying drug/lipid ratios fitted best to the 
Higuchi square root model for microspheres 
with the composition 1:4:1 drug-lipid ratio 
[14].  
 
The objective of this study was to develop a 
new indomethacin controlled release solid 
dosage form using alcohol and chlorophorm 






Raw propolis was obtained from Sari 
(Mazandaran, Iran) bee keepers in autumn 
2006 A sample (voucher no. 110 NTMRC) 
was kept at the herbarium of Traditional 
Medicine & Materia Medica Research Center 
(TMRC), Shaheed Beheshti University of 
Medical Sciences, Tehran, Iran. The propolis 
was kept in a desiccator in the dark until it 
was processed. Indomethacin, lactose and 
HPLC grade methanol were obtained from 
Merck (Darmstadt, Germany) while quercetin, 
kaempferol, naringenin, Chrysin and galangin 
were supplied by Extrasynthese (Genay, 
France). 
 
Preparation propolis extracts 
 
Ethanol extract of propolis (EEP) was then 
frozen at -10 °C, ground into powder in a 
mortar with a pestle. The powder was 
dispersed in 80 % ethanol (15 ml of ethanol/g 
of propolis) at 40 °C and shaken for 8 h. The 
mixture was filtered through Whatman filter 
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paper no. 1 and the extract concentrated to 
the past in a rotary evaporator under reduced 
pressure at 40 °C. The residue was redissol-
ved in a minimal volume 0.5-1 ml of 96 % 
ethanol and kept at room temperature in the 
dark until use. The chloroform extract of 
propolis (CEP) way similarly obtained with 
chloroform used instead of ethanol. 
 
Standardization of propolis extracts 
 
The propolis extracts (EEP and CEP) were 
standardized using USP 25 procedures for 
the determination of parameters for fat and 
fixed oil, including acid, ester , hydroxyl , 
iodine and saponification values[15].  
 
HPLC characterization of the extracts 
 
Standardiztion was followed by HPLC 
characterization of the extracts using various 
flavonoids (quercetin, kaempferol, naringenin, 
chrysin and galangin) as standards [16]. The 
HPLC system  (Knauer, Germany) consisted 
of a model K-1001 solvent delivery system 
equipped with a Rheodyn injection valve (20 
µl sample loop inserted) and a UV-Vis 
spectrophotometric detector model K-2600 
set at 360 nm (Knauer Associates, 
Germany). The analysis was performed using 
a ODS-C18 column (250 × 4.6 mm i.d., 5 µm 
particle size, Shim-Pack Vp-ODS) and the 
corresponding guard column (5 × 4.6 mm i.d., 
5 µm particle size). All solvents were filtered 
and degassed before entering the column. 
The optimal conditions for the separation of 
five flavonoids were determined using 
Reverse phase (RP)-HPLC. The mobile 
phase was methanol: 30mM NaH2PO4 (40:60 
v/v) adjusted to pH 3 while the mobile phase 
flow rate was 1.5 ml/min. All measurments 
were made at ambient temprature. 
 
Preparation indomethacin capsule 
formulations 
 
The desired amount of indomethacin was 
weighed and mixed with varying amounts of 
CEP and EEP dissolved in 0.5 ml chloroform 
and ethanol, respectively (Table 1). In each 
case, the mixture, after evapotation of 
solvent, was passed through a sieve with 
aperture of 850 µm. Granules retained on the 
sieve were filled manually in capsule shells 
such that each capsule contained 75 mg 
indomethacin. 
 
Table 1: Composition of 75 mg indomethacin 
capsule formulations. Note: F1 – F13 contained 
chloroform extract of propolis (CEP) while F14 – 








F1 0.75 99.25 
F2 1.5 98.5 
F3 2.25 97.75 
F4 3 97 
F5 3.75 96.25 
F6 7.5 92.5 
F7 30 70 
F8 33.75 66.25 
F9 37.5 62.5 
F10 41.25 58.75 
F11 45 55 
F12 60 40 
F13 75 25 
F14 30 70 
F15 45 55 
F16 60 40 
F17 75 25 
F18 0 100 
  
Drug release studies  
 
In vitro release of indomethacin from the 
capsule formulations was determined using a 
standard USP 30 NF 25 dissolution test 
apparatus (rotating basket/method I, Erweka 
DT 80, Germany) at 100 rpm in 1 L of 0.01M 
hydrochloric acid (pH = 1.2) for 30 min and 
subsequently in1 litter of phosphate buffer 
(pH 6.2) at 37 ºC for 12 h. At predetermined 
time intervals, 5 ml aliquot samples were 
withdrawn from the dissolution medium, 
filtered through Whatman filter paper no. 1 
and immediately replaced with the same 
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volume of fresh dissolution medium. 
Indomethacin content was determined 
spectrophotometrically (Genesys TM2, USA) 
at 318 nm. All determinations were in 
triplicate. 
 
Differential scanning calorimetry (DSC) 
studies 
 
Differential scanning calorimetric assessment 
of indomethacin, the individual extracts as 
well as selected blends of the drug and 
extracts were conducted in a Perkin Elmer 
(Germany) DSC apparatus using an accurate 
weight (~10 mg) of the sample in a loosely 
covered aluminum pan and heated from 50 to 
300 °C at 10°C/min rate under nitrogen 
atmosphere. An empty loosely covered 
aluminum pan was used as the reference.  
 
Kinetic analysis drug release data 
 
To determine the release mechanisms of the 
formulations, the in vitro release data were 
subjected to various release kinetic models - 
zero-order, first-order, Higuchi, Korsemeyer-
Peppas and Weibull with a view to obtaining 




The results obtained are expressed as mean 
± standard deviation (SD). Student’s t-test 
and one-way analysis of variance (ANOVA) 
were applied to check significant differences 
in drug release data between formulations 
using Sigma Plot 5 software.  Differences 
were considered statistically significant at p < 




Propolis standardization  
 
Figure 1A shows the chromatogram (with 
retention times) of five flavonoid standards, 
namely, narginin (3.4 min), quercetin (5.3 
min), kaemferol (7.2 min), chrysin (15.4 min) 
and galangine (17.8 min). Figure 1B shows 
the chromatogram of EEP with all the peaks 
clearly resolved in base, except chrysin, while 
CEP chromatogram included quercetin, 
















Figure 1: Representative HPLC chromatogram (A) 
of five flavonoid standards containing narginin (3.4 
min.), quercetin (5.3 min.), kaemferol (7.3 min.), 
chrysin (15.4 min.) and galangine (17.8 min.); EEP 
chromatogram (B); and CEP chromatogram (C) 
 
The results showed that due to existence of 
interferences at the ethanol and chloroform 
extract, peak overlapping was observed at 
15.4 and 17.8 minute, respectively. 
Therefore, chrysin in the EEP and galangine 
in the CEP chromatogram are not detectable. 
Acid, ester, hydroxyl and saponification 
values for CEP were found 0.8, 78.54, 68.73 




Indomethacin release from all the 
formulations was ≤ 4.5 % in 30 min in 
simulated gastric fluid (pH 1.2). The plots of 
the entire drug release data as a function of 
time, shown in Fig 2, indicate that there was 
no significant difference between 
formulations F1 – F7 and F18 which was the 
blank (p > 0.05), but the other formulations 
exhibited significant reduction in drug release 
compared with F18 (p < 0.05). Fig 2 shows 
the release profile of indomethacin with 
different percents of propolis. One way 
analysis of variance (ANOVA), indicated 
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profile of indomethacin, in capsules included 
propolis more than 33.75 mg per capsule. 
 
F13, which represents a drug/CEP ratio of 
1:1, produced the most pronounced decrease 
in drug release. Overall, the results show that 
using CEP produced significantly slower 





Figure 2: Dissolution profile (n = 3) of 
indomethacin capsule formulations containing 
propolis matrix; A = CEP-indomethacin 
formulations (□ = F7, ◊ = F8,▲ = F9, ▼= F10, ∆ = 
F11,   ○ = F12, ∆  = F13, ● = F18); B = EEP-
indomethacin formulations (□ = F14, ▲ = F15,  ○ = 
F16, □ = F17, ● = F18 (see Table 1 for codes). 
Maximum release % in acidic medium <5%. 
 
Drug release kinetics  
 
Kinetic analysis of the in vitro release of the 
formulations indicate that the best-fit drug 
release model varied with the drug:propolis 
extract ratio of the formulations. All the 
derived kinetic parameters including rate 
constants are shown in Table 2. For the 
Korsemeyer-Peppas model, diffusional 
exponent, n, is a factor which indicates the 
mechanism of the release. For instance n:0.5 
for square root of time (~F8, F9-F11, and 
F12) and n:1 for zero order release(~F13). 
The values of n>1.0 indicates anomalous 
diffusion for F14-F17 formulations. The 
results in Table 2 show that the value of n 
increased when CEP content was increased 
(F7 to F13). F13 formulation fitted best to 




The DSC thermograms obtained are shown 
in Fig 3.  They indicate a sharp endothermic 
peak at 165 ºC for pure indomethacin (B) aas 
well as a range of weak endothermic peaks 
from 100 to 200 ºC and 30 to 100 ºC for pure 
EEP (A) and CEP (C), respectively. These 
peaks can be attributed to melting transitions 
of the various lipids in the extract. Blending of 
propolis with indomethacin led to depression 
of the latter’s melting point in all the 
formulations (D, E and F). The magnitude of 
these depressions were 5, 20 and 30 ºC for 
F9, F13 and F17, respectively, which indicate 
probable interaction between the drug and 




In vitro dissolution test is an important tool for 
evaluating the quality of dosage forms 
obtained from various sources. It is also aids 
in assessing the capacity of a formulation to 
deliver the required active substance 
effectively to the patient.  
 
The results indicate that indomethacin from 
the capsule formulations was pH-dependent, 
with < 5% of the drug released at acidic pH. 
The formulations showed a relatively rapid 
initial drug release during the first hour, 
followed by a slower release rate, except 
F13, which showed a relatively constant 
release rate. The initial rapid drug release 
may be due to the formation of a solid 
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Table 2: Kinetic release parameters for indomethacin/propolis capsule formulations based on various 
release models  
 






Fig 3: Differential scanning calorimetry (DSC) 
thermograms of (A) pure EEP, (B) pure 
indomethacin, (C) pure CEP, (D) F9 – drug/CEP 
(1:0.5), (E) F13 – drug/CEP (1:1), and (F) F17 - 
drug/EEP (1:1) 
 
the surface of the granules; on the other 
hand, the drug present in the deeper 
interstices of the granules was released at a 
slower  rate  [17].   The  slower  but  steadier 
release of F13 (in which the ratio of CEP to 
indomethacin was 1:1) is probably due to 
complete coating of the drug particles by 
CEP, would have hindered the penetration of 
the dissolution medium through the matrix.  
 
As stated earlier, the mode of drug release 
from waxy matrices is usually by 
erosion/diffusion of drugs [8]. There are 
different possible mechanisms by which this 
occurs. The first and most often encountered 
mechanism is drug diffussion through   the 
outside layers of the matrix, and is known as 
“Fickian” release. The second mechanism is 
non-Fickian or anomalous transport while the 
third is “zero-order” release mechanism. All of 
the formulations exhibited retarded release of 
drug. However, increasing the ratio of 
propolis extracts resulted in further decrease 
in the drug release. Therefore, the dissolution 
medium slowly penetrated the granules, 
resulting in a slow release of the drug. In the 
present study, drug release from F13 
exhibited zero order kinetics which means 
that although the formulation was a matrix 
system, the CEP coating around the drug 
particles functioned as a memberane system 
through which controlled drug diffusion 
occurred. Apparently, in formulations F1 to 
F12, there was insufficient matrix material to 
form a membrane system, and hence release 
did not follow zero order.  
 
Drug release from non-swellable matrices is 
governed primarily by diffusion [17]. The rate 
of drug release from matrix systems 
decreases as a function of time because the 
diffusional path length for drug release 
decreases with time as the solvent front 











K r K r K r K r n K r 
F7 4.432 0.966 0.103 0.983 0.203 0.991 0.261 0.994 0.431 0.136 0.985 
F8 4.903 0.972 0.123 0.982 0.223 0.993 0.254 0.995 0.464 0.153 0.981 
F9 4.855 0.977 0.126 0.982 0.221 0.995 0.269 0.997 0.445 0.161 0.982 
F10 4.396 0.981 0.103 0.988 0.202 0.996 0.268 0.996 0.415 0.135 0.981 
F11 4.954 0.968 0.118 0.995 0.228 0.993 0.231 0.991 0.504 0.147 0.994 
F12 5.012 0.969 0.116 0.992 0.229 0.997 0.217 0.995 0.522 0.137 0.994 
F13 6.143 0.992 0.122 0.986 0.277 0.989 0.809 0.991 0.869 0.107 0.987 
F14 3.575 0.741 0.030 0.671 0.231 0.855 0.825 0.956 1.441 0.526 0.987 
F15 3.661 0.743 0.031 0.675 0.236 0.937 0.855 0.937 1.415 0.489 0.982 
F16 3.708 0.749 0.032 0.682 0.239 0.976 0.788 0.976 1.226 0.487 0.978 
F17 3.830 0.777 0.033 0.704 0.245 0.947 0.872 0.947 1.332 0.462 0.989 
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absence of positive deviation from linearity 
indicates that the drug is released primarily 
by diffusion and that erosion contributes 
negligibly. F13 formulation showed an 
optimal drug release properties as it closely 
approximated zero order. It seems that the 
dissolution of drug particles at the surface of 
other formulations allowed the establishment 
of channels in the matrix through which drug 
was released. Hence, release rate was 
higher in these formulations [18].  
 
The values of the diffusional exponent, n, for 
the formulations was derived from the 
Korsemeyer-Peppas model (where n is a 
factor which indicates the mechanism of the 
release). For example, n = 0.5 (indicating 
diffusion-controlled drug release) and n = 1.0 
(indicating swelling-controlled drug release). 
and n > 1.0 for anomalous diffusion. It is 
important to note that two extreme values for 
the exponent n, 0.5 and 1.0, are valid for only 
slab geometry. For spheres and cylinders, 
different values have been derived,  
 
Another effective factor that influences drug 
release from a matrix system is the 
hydrophobicity of the matrix. The faster 
release of drugs formulated with the ethanol 
extract of propolis can be attributed in part to 
the higher hydrophobicity of the extract in 
which indomethacin (which itself is also a 
very hydrophobic drug) would readily 
disperse/dissolve in the solid state. In such 
circumstances, the drug would diffuse faster 




Our results show that CEP can be offered as 
a matrix material for sustained release of 
indomethecin and similarly hydrophobic 
drugs if used in a suitable proportion in 
relation to the drug. Such a delivery system 
would release drug by diffusion and/or 
erosion mechanisms. The advantage of 
propolis as a natural product is that it is more 
likely to be compatible with human body than 
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